Drugs / E303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07524348 | Mar 2026 → Jul 2030 expected | cancer | Samsung Bioepis Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524348 ↗ |
| Route | Intravenous | “intravenous (IV) infusion of E303” NCT07524348 ↗ |